Lipocine opens two new markets for oral testosterone as it advances postpartum depression drug

Lipocine Inc. has secured a second regulatory clearance for its oral testosterone capsule outside the US, with Health Canada approving the product in September for men with hypogonadism. The company disclosed the decision on 5 November alongside results for the quarter ended 30 September 2026.

The financial picture remains modest. Lipocine posted revenue of $2.3 million and a net loss of $0.7 million for the quarter, with most of the revenue coming from licence and collaboration income rather than product sales. The facts provided do not break down the sources of that income further.

The Canadian approval covers testosterone undecanoate capsules sold as TLANDO. The United Arab Emirates authorised the same product in July 2026 under the name TESTYRA. Lipocine intends to launch in both countries in early 2027. No pricing, partner or sales forecast details were included in the material available.

Lipocine has also started BLOOM, a Phase 3 study of LPCN 1154, an oral version of brexanolone, in postpartum depression. The company says the trial is meant to support a 505(b)(2) new drug application and follows feedback from the US Food and Drug Administration. No information on trial design, enrolment or timelines was provided.

Context: a 505(b)(2) application is a US regulatory route that lets a sponsor lean partly on existing information, such as published literature or earlier agency findings, instead of producing every piece of evidence itself.